Encompass Health (NYSE:EHC) PT Raised to $117.00 at KeyCorp

Encompass Health (NYSE:EHC) had its target price hoisted by equities research analysts at KeyCorp from $115.00 to $117.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. KeyCorp’s price target suggests a potential upside of 25.63% from the stock’s current price.

Several other equities analysts have also recently commented on EHC. Leerink Partnrs upgraded Encompass Health to a “strong-buy” rating in a research report on Wednesday, July 10th. Barclays cut their price objective on Encompass Health from $113.00 to $109.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. UBS Group raised their target price on shares of Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Truist Financial increased their price target on shares of Encompass Health from $104.00 to $108.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Finally, Stephens reaffirmed an “overweight” rating and set a $105.00 price objective on shares of Encompass Health in a report on Tuesday, August 6th. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $104.89.

Encompass Health Trading Down 0.4 %

Shares of EHC stock opened at $93.13 on Tuesday. Encompass Health has a 12-month low of $59.57 and a 12-month high of $98.74. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 1.08. The company has a 50 day moving average of $93.67 and a 200-day moving average of $88.39. The firm has a market cap of $9.37 billion, a P/E ratio of 23.76, a PEG ratio of 1.45 and a beta of 0.88.

Encompass Health (NYSE:EHC) last issued its earnings results on Monday, August 5th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.10. Encompass Health had a net margin of 7.88% and a return on equity of 17.83%. The business had revenue of $1.30 billion for the quarter, compared to analysts’ expectations of $1.30 billion. During the same quarter in the previous year, the firm posted $0.95 EPS. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. Sell-side analysts anticipate that Encompass Health will post 4.18 earnings per share for the current year.

Encompass Health announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, July 24th that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the company to purchase up to 5.4% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity at Encompass Health

In other Encompass Health news, CFO Douglas E. Coltharp sold 12,260 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total value of $1,058,528.40. Following the completion of the sale, the chief financial officer now owns 136,227 shares in the company, valued at approximately $11,761,839.18. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. UMB Bank n.a. increased its holdings in shares of Encompass Health by 387.7% in the 3rd quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after purchasing an additional 252 shares in the last quarter. V Square Quantitative Management LLC lifted its holdings in shares of Encompass Health by 53.0% during the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock valued at $39,000 after buying an additional 140 shares during the period. Oakworth Capital Inc. purchased a new stake in Encompass Health during the second quarter valued at $40,000. Benjamin F. Edwards & Company Inc. boosted its position in Encompass Health by 58.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company’s stock worth $46,000 after purchasing an additional 198 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Encompass Health in the 2nd quarter worth approximately $58,000. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.